# Immune Responses to Two Dose Varivax +/- MMR-II

> **NCT00258726** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 105 (—)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** MMR-II
- **BIOLOGICAL:** Pro-Quad
- **BIOLOGICAL:** Varivax

## Key facts

- **NCT ID:** NCT00258726
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 105 (—)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258726, "Immune Responses to Two Dose Varivax +/- MMR-II". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00258726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*